These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 19589098

  • 1. Immunotoxicity profile of natalizumab.
    Wehner NG, Gasper C, Shopp G, Nelson J, Draper K, Parker S, Clarke J.
    J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
    [Abstract] [Full Text] [Related]

  • 2. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor.
    Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Apr; 86(2):144-56. PubMed ID: 19283860
    [Abstract] [Full Text] [Related]

  • 3. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor.
    Wehner NG, Shopp G, Oneda S, Clarke J.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Apr; 86(2):117-30. PubMed ID: 19278014
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH, Bressler B.
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
    [Abstract] [Full Text] [Related]

  • 5. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK.
    Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
    [Abstract] [Full Text] [Related]

  • 6. Immune surveillance in multiple sclerosis patients treated with natalizumab.
    Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK.
    Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
    [Abstract] [Full Text] [Related]

  • 7. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells.
    Putzki N, Baranwal MK, Tettenborn B, Limmroth V, Kreuzfelder E.
    Eur Neurol; 2010 May; 63(5):311-7. PubMed ID: 20453514
    [Abstract] [Full Text] [Related]

  • 8. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.
    Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R, Meinl E.
    Neurology; 2008 Oct 21; 71(17):1350-4. PubMed ID: 18936427
    [Abstract] [Full Text] [Related]

  • 9. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study.
    Weinberg AD, Thalhofer C, Morris N, Walker JM, Seiss D, Wong S, Axthelm MK, Picker LJ, Urba WJ.
    J Immunother; 2006 Oct 21; 29(6):575-85. PubMed ID: 17063120
    [Abstract] [Full Text] [Related]

  • 10. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B, Kappos L.
    Neurodegener Dis; 2008 Oct 21; 5(1):16-22. PubMed ID: 18075270
    [Abstract] [Full Text] [Related]

  • 11. Phenotypic analysis of splenocyte subsets following acute morphine treatment in the rat.
    Fecho K, Lysle DT.
    Cell Immunol; 1999 Aug 01; 195(2):137-46. PubMed ID: 10448013
    [Abstract] [Full Text] [Related]

  • 12. Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.
    Zanotti C, Chiarini M, Serana F, Sottini A, Garrafa E, Torri F, Caimi L, Rasia S, Capra R, Imberti L.
    Clin Immunol; 2012 Oct 01; 145(1):19-26. PubMed ID: 22892399
    [Abstract] [Full Text] [Related]

  • 13. Natalizumab effects on immune cell responses in multiple sclerosis.
    Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, Trigueiro M, Racicot D, Guérette C, Antel JP, Fournier A, Grand'Maison F, Bar-Or A.
    Ann Neurol; 2006 May 01; 59(5):748-54. PubMed ID: 16634035
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients.
    Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L.
    J Neuroimmunol; 2008 Feb 01; 194(1-2):153-64. PubMed ID: 18178259
    [Abstract] [Full Text] [Related]

  • 15. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, Harrer A, Huemer M, Kunz A, Golaszewski S, Staffen W, Ladurner G, Kraus J.
    Mult Scler; 2011 Jan 01; 17(1):16-23. PubMed ID: 20937631
    [Abstract] [Full Text] [Related]

  • 16. Reply to "'Thinking without thinking' about natalizumab and PML".
    Houff S, Berger JR.
    J Neurol Sci; 2008 Jan 15; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
    [No Abstract] [Full Text] [Related]

  • 17. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA, Sandrock A.
    Expert Rev Neurother; 2004 Jul 15; 4(4):571-80. PubMed ID: 15853576
    [Abstract] [Full Text] [Related]

  • 18. The effects of natalizumab on the innate and adaptive immune system in the central nervous system.
    Stüve O.
    J Neurol Sci; 2008 Nov 15; 274(1-2):39-41. PubMed ID: 18474372
    [Abstract] [Full Text] [Related]

  • 19. Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis.
    Coisne C, Mao W, Engelhardt B.
    J Immunol; 2009 May 15; 182(10):5909-13. PubMed ID: 19414741
    [Abstract] [Full Text] [Related]

  • 20. [Natalizumab in the treatment of multiple sclerosis].
    Horga A, Horga de la Parte JF.
    Rev Neurol; 2009 May 15; 45(5):293-303. PubMed ID: 17876741
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.